BR112018017324A2 - derivado de 5-metil-6-fenil-4,5-di-hidro-2h-piridazin-3-ona - Google Patents

derivado de 5-metil-6-fenil-4,5-di-hidro-2h-piridazin-3-ona

Info

Publication number
BR112018017324A2
BR112018017324A2 BR112018017324-0A BR112018017324A BR112018017324A2 BR 112018017324 A2 BR112018017324 A2 BR 112018017324A2 BR 112018017324 A BR112018017324 A BR 112018017324A BR 112018017324 A2 BR112018017324 A2 BR 112018017324A2
Authority
BR
Brazil
Prior art keywords
pyridazin
dihydro
phenyl
derivative
methyl
Prior art date
Application number
BR112018017324-0A
Other languages
English (en)
Other versions
BR112018017324B1 (pt
Inventor
Katoh Takahiro
Iida Masatoshi
Terauchi Yuki
Yamaguchi Kazuya
Hirose Toshiyuki
Yokoyama Fumiharu
Nishimori Hikaru
Obuchi Yutaka
Nabeshima Hiroshi
Takaki Emiri
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of BR112018017324A2 publication Critical patent/BR112018017324A2/pt
Publication of BR112018017324B1 publication Critical patent/BR112018017324B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

a presente invenção refere-se a um agente para tratamento de tumor maligno compreendendo um composto da fórmula (1): em que r1 a r4 são átomo de hidrogênio, halogênio ou etc., y é grupo alquileno opcionalmente substituído ou etc.
BR112018017324-0A 2016-03-04 2017-03-02 Derivado de 5-metil-6-fenil-4,5-di-hidro-2h-piridazin-3-ona BR112018017324B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-042535 2016-03-04
JP2016042535 2016-03-04
PCT/JP2017/008246 WO2017150654A1 (en) 2016-03-04 2017-03-02 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative

Publications (2)

Publication Number Publication Date
BR112018017324A2 true BR112018017324A2 (pt) 2018-12-26
BR112018017324B1 BR112018017324B1 (pt) 2024-03-19

Family

ID=

Also Published As

Publication number Publication date
SI3423440T1 (sl) 2021-07-30
MX2018010535A (es) 2019-01-10
EA201891987A1 (ru) 2019-02-28
PH12018501873A1 (en) 2019-01-28
US10611731B2 (en) 2020-04-07
EP3423440B9 (en) 2021-07-28
EP3423440B1 (en) 2021-01-06
HUE053358T2 (hu) 2021-06-28
KR20180118717A (ko) 2018-10-31
AU2021201135A1 (en) 2021-03-11
EP3423440A1 (en) 2019-01-09
ZA201805791B (en) 2021-04-28
JP6596595B2 (ja) 2019-10-23
MY196801A (en) 2023-05-03
DK3423440T3 (da) 2021-03-15
TWI731041B (zh) 2021-06-21
PT3423440T (pt) 2021-03-11
LT3423440T (lt) 2021-06-10
CY1123927T1 (el) 2022-05-27
SG11201807146SA (en) 2018-09-27
IL261225A (en) 2018-10-31
JP2019506432A (ja) 2019-03-07
CN108779076B (zh) 2022-05-03
US20210171472A1 (en) 2021-06-10
AU2017226674A1 (en) 2018-09-13
IL261225B (en) 2021-08-31
HRP20210395T1 (hr) 2021-04-16
CN108779076A (zh) 2018-11-09
WO2017150654A1 (en) 2017-09-08
ES2862177T3 (es) 2021-10-07
RS61593B1 (sr) 2021-04-29
AU2021201135B2 (en) 2022-09-01
AU2017226674B2 (en) 2020-12-03
TW201736350A (zh) 2017-10-16
PL3423440T3 (pl) 2021-07-26
NZ745688A (en) 2023-02-24
US20200181092A1 (en) 2020-06-11
SA518392275B1 (ar) 2021-10-11
EA036423B1 (ru) 2020-11-10
KR102350772B1 (ko) 2022-01-14
CA3015331A1 (en) 2017-09-08
US20190023662A1 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
CR20170118A (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
BR112017003898A2 (pt) análogos de dioxolano de uridina para o tratamento de câncer
BR112016013874A2 (pt) Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêutica
BR112017018305A2 (pt) desacetoxitubulisina h e análogos da mesma
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
BR112016018851A8 (pt) processo para fornecer um composto de fórmula (iv)
MX2018016290A (es) Agente antidesgaste.
EA201792287A1 (ru) Способы лечения рака
BR112021006229A2 (pt) composto, composição farmacêutica, e, método para tratamento de um câncer
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d'utilisation associés
BR112018001726A2 (pt) inibidores do vírus sincicial respiratório
AR105540A1 (es) Inhibidores de fucosidasas
MX2016006744A (es) Inhibidores de tirosina cinasa de bruton.
BR112015020834A2 (pt) novos derivados hidroquinolina-2-ona como inibidores de aldosterona sintetase (cyp1 1 b2 ou cyp1 1 b1)
EA201792288A1 (ru) Способы лечения рака
BR112014030474A2 (pt) novos compostos bicíclicos de tiofenilamida
PH12018501873A1 (en) 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/03/2017, OBSERVADAS AS CONDICOES LEGAIS